Drug Profile
Lacnotuzumab - Novartis Oncology
Alternative Names: Anti-M-CSF-antibody; MCS-110Latest Information Update: 10 Mar 2023
Price :
$50
*
At a glance
- Originator Novartis
- Developer Dana-Farber Cancer Institute; Novartis; Novartis Oncology; Seoul National University Hospital
- Class Anti-inflammatories; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Macrophage colony stimulating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gastric cancer; Giant cell tumour of tendon sheath; Pigmented villonodular synovitis; Triple negative breast cancer
- Phase I/II Malignant melanoma; Solid tumours
- Discontinued Bone metastases; Prostate cancer
Most Recent Events
- 06 Feb 2023 Novartis terminates a phase Ib trial in Triple negative Breast cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or grater) in USA, Australia, Hong Kong, Israel, Italy, Japan, Netherlands, Singapore and Spain (IV, infusion), based on sponsored decision (NCT03742349)
- 28 Feb 2022 No recent reports of development identified for phase-I development in Triple negative Breast-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Israel, Spain, Netherlands, Japan, Italy, Hong Kong, Australia, USA (IV, Infusion)
- 10 Apr 2021 Efficacy and pharmacodynamics data from a phase I/II trial in Solid tumours presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)